

PI3K $\delta$ -IN-25

## Chemical Properties

CAS No. :

Formula:

Molecular Weight:

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.

## Biological Description

|                            |  |
|----------------------------|--|
| Description                | PI3K $\delta$ -IN-25 is an orally active and selective PI3K $\delta$ inhibitor with an IC <sub>50</sub> of 2.1 nM. It exhibits IC <sub>50</sub> values of 272, 285, and 1171 nM for PI3K $\alpha$ , PI3K $\gamma$ , and PI3K $\beta$ , respectively. In B16F10 cells, PI3K $\delta$ -IN-25 inhibits the phosphorylation of AKTSer473, suppresses Treg cell proliferation, and downregulates the expression of PD-L1. In mouse models of B16F10 melanoma and Lewis lung cancer, PI3K $\delta$ -IN-25 demonstrates anticancer activity by reducing tumor-infiltrating Treg cells and enhancing immune responses. This compound is applicable for research on cancers such as melanoma and lung cancer.   |
| Targets(IC <sub>50</sub> ) | Akt,PD-1/PD-L1,Integrin,Interleukin,PI3K   |
| In vitro                   | PI3K $\delta$ -IN-25 (Compound 18) at 1 $\mu$ M effectively inhibits PIK3CD (93.37%), PIK3CG (87.63%), and PIK3CA (107.38%), while showing moderate activity against RIPK2 (58.65%) and PIK3CB (42.68%). After a 96-hour exposure, PI3K $\delta$ -IN-25 demonstrates anti-proliferative effects on Ramos, DOHH2, Hela, BxPC3, SGC7901, BGC823, MX-1, A375, and B16F10 cells with IC <sub>50</sub> values of 18.11, 14.39, 29.51, 22.13, 15.81, 13.06, 25.43, 21.95, and 11.42 $\mu$ M respectively, while exhibiting weaker activity on K562, HepG2, and MCF-7 cells with IC <sub>50</sub> values greater than 50 $\mu$ M. Additionally, PI3K $\delta$ -IN-25 (1-10 $\mu$ M, 5-30 minutes) inhibits AKT Ser473 phosphorylation, indicating blockage of the PI3K signaling pathway in B16F10 cells. At concentrations of 1-10 $\mu$ M over 72 hours, PI3K $\delta$ -IN-25 reduces the proportion of CD4/CD25/FOXP3+++ as well as IL-10 concentration in mIL-2 and hTGF $\beta$ -induced Treg cells; at 10 $\mu$ M, it downregulates PD-L1 expression in B16F10 cells. |
| In vivo                    | PI3K $\delta$ -IN-25 (Compound 18) administered orally at doses of 1-30 mg/kg twice daily, suppresses tumor growth by modulating the tumor microenvironment in both B16F10 and Lewis xenograft mouse models.   |

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286

E\_mail:info@targetmol.com

Address:34 Washington Street,Wellesley Hills,MA 02481